W. Bradford Smith
Independent DirectorMr. W. Bradford Smith, also known as Brad, CPA, M.B.A. served as the Chief Business Officer at Homology Medicines, Inc. since March 2022 until November 2023. He served as the Chief Financial Officer and Treasurer of Homology Medicines, Inc. since April 4, 2017 until 2023 and had been its Secretary since July 2017 until June 2020. Mr. Smith has been an Independent Director of Lyra Therapeutics, Inc. since November 2019. Since December 2024, Mr. Smith has served as the Chief Financial Officer of Incendia Therapeutics, Inc. Mr. Smith served as a Consultant of Ocular Therapeutix, Inc. from April 1, 2017 to May 31, 2017 and served as its Chief Financial Officer since March 2014 until April 2017 and served as its Chief Accounting Officer until March 31, 2017. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc. Mr. Smith has expertise in the life sciences, biotechnology and healthcare industry including private equity financings, initial public offerings, Investor Relations, business development initiatives and strategic planning. He served as the Chief Financial Officer of OmniGuide, Inc since July 2008 to March 2014. Mr. Smith served as the Chief Financial Officer of Neurometrix Inc. from February 14, 2005 to June 30, 2008 and served as its Principal Accounting Officer and Secretary. He served as Chief Financial Officer of Patientkeeper, Inc. Prior to joining Neurometrix Inc. he served as the Chief Financial Officer and Executive Vice President at Synarc, Inc. and served as its Vice President of Finance. He was responsible for global financial operations, raised private equity financing from several venture capital firms and completed the acquisition of a medical imaging services company. Prior to Synarc, he was at PatientKeeper, a company providing healthcare professionals with mobile computing solutions. At PatientKeeper, he was instrumental in raising private funding with venture capital and strategic Investors and helping Neurometrix Inc. launch its initial products. He worked at StemCells Inc. He served as the Chief Financial Officer of Focal, Inc. and led it through several rounds of private and public equity financing including management of its initial public offering. Prior to Focal, he served as Director of Finance and Treasurer of CytoTherapeutics, where he played a key role in raising capital for two private placements and its initial public offering. Previous expertise includes financial roles at ImmuCell Corporation and Senior Financial Analyst in mergers & acquisitions at Sanders Associates, a division of Lockheed Corp. He served as Senior Accountant of PricewaterhouseCoopers LLP (formerly, Coopers & Lybrand). Since May 2021, Mr. Smith has served on the board of directors of eGenesis, a private gene editing company. He holds MBA from the Whittemore School of Business and Economics at the University of New Hampshire. He holds Certified Public Accountant designation in 1983 and has a Bachelor of Science degree in biology from Tufts University in Boston, MA.
Positions
- Company NameLyra Therapeutics, Inc.Stock CodeLYRAPositionIndependent DirectorColleagues
- CSCarmichael S. RobertsCo-Founder
- CAC. Ann MerrifieldIndependent Director
- VBVineeta BelangerSenior Vice President of Clinical Affairs
- ANAllison NanceSenior Vice President of Regulatory Affairs
- ERElazer R. EdelmanVP of Finance & Risk
- JRJames R. TobinLead Independent Director
- NLNancy L. SnydermanIndependent Director
